Vir Biotechnology (NASDAQ:VIR) is a clinical-stage immunology company headquartered in San Francisco, California, focused on developing treatments for serious infectious diseases. Founded in 2017, the company integrates cutting-edge immunologic insights with proprietary technology platforms to advance a pipeline of monoclonal antibodies, small molecules and vaccines. By targeting both the immune system and specific pathogens, Vir seeks to deliver innovative therapies that address unmet medical needs in areas such as respiratory viruses, hepatitis, HIV and tuberculosis.
A cornerstone of Vir’s portfolio is its collaboration with GlaxoSmithKline (GSK), through which the companies co-developed sotrovimab, a monoclonal antibody authorized for the treatment and prevention of COVID-19 in high-risk populations. Beyond COVID-19, Vir’s research efforts extend to next-generation antibody candidates aimed at influenza, hepatitis B virus (HBV) and hepatitis C virus (HCV), as well as investigational agents targeting human immunodeficiency virus (HIV) and Mycobacterium tuberculosis. The company’s proprietary platforms—including its Monoclonal Antibody Discovery (MAb) and Analog-to-clinic technologies—support rapid identification, optimization and scaling of biologic candidates.
In addition to its San Francisco headquarters, Vir maintains research and development facilities in the United Kingdom and collaborates with manufacturing partners across North America, Europe and Asia. These global activities enable the company to advance clinical trials efficiently, engage regulatory authorities and build a diversified network for commercial supply. Vir’s partnerships extend to Alnylam Pharmaceuticals in the RNA interference space, Biogen for neurological applications and other strategic alliances that leverage complementary expertise and resources.
Vir Biotechnology’s leadership team is composed of seasoned biopharmaceutical executives, led by Chief Executive Officer George Scangos, Ph.D., who brings decades of experience in steering biotechnology enterprises from early research through commercialization. Supported by a board of directors and scientific advisory board with backgrounds in immunology, infectious diseases and clinical development, Vir continues to pursue its mission of harnessing the immune system to prevent and treat human disease on a global scale.
